228 related articles for article (PubMed ID: 25600590)
1. Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation.
Wang L; Liu R; Ye P; Wong C; Chen GY; Zhou P; Sakabe K; Zheng X; Wu W; Zhang P; Jiang T; Bassetti MF; Jube S; Sun Y; Zhang Y; Zheng P; Liu Y
Nat Commun; 2015 Jan; 6():5909. PubMed ID: 25600590
[TBL] [Abstract][Full Text] [Related]
2. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
[TBL] [Abstract][Full Text] [Related]
3. A CD24-p53 axis contributes to African American prostate cancer disparities.
Liu W; Zhang Y; Wei S; Bae S; Yang WH; Smith GJ; Mohler JL; Fontham ETH; Bensen JT; Sonpavde GP; Chen GY; Liu R; Wang L
Prostate; 2020 May; 80(8):609-618. PubMed ID: 32168400
[TBL] [Abstract][Full Text] [Related]
4. AKT regulates NPM dependent ARF localization and p53mut stability in tumors.
Hamilton G; Abraham AG; Morton J; Sampson O; Pefani DE; Khoronenkova S; Grawenda A; Papaspyropoulos A; Jamieson N; McKay C; Sansom O; Dianov GL; O'Neill E
Oncotarget; 2014 Aug; 5(15):6142-67. PubMed ID: 25071014
[TBL] [Abstract][Full Text] [Related]
5. Sumoylation induced by the Arf tumor suppressor: a p53-independent function.
Tago K; Chiocca S; Sherr CJ
Proc Natl Acad Sci U S A; 2005 May; 102(21):7689-94. PubMed ID: 15897463
[TBL] [Abstract][Full Text] [Related]
6. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.
Zhang W; Yi B; Wang C; Chen D; Bae S; Wei S; Guo RJ; Lu C; Nguyen LL; Yang WH; Lillard JW; Zhang X; Wang L; Liu R
Clin Cancer Res; 2016 May; 22(10):2545-54. PubMed ID: 26712693
[TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.
Korgaonkar C; Hagen J; Tompkins V; Frazier AA; Allamargot C; Quelle FW; Quelle DE
Mol Cell Biol; 2005 Feb; 25(4):1258-71. PubMed ID: 15684379
[TBL] [Abstract][Full Text] [Related]
8. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.
Dreidax D; Gogolin S; Schroeder C; Muth D; Brueckner LM; Hess EM; Zapatka M; Theißen J; Fischer M; Ehemann V; Schwab M; Savelyeva L; Westermann F
Hum Mol Genet; 2013 May; 22(9):1735-45. PubMed ID: 23343716
[TBL] [Abstract][Full Text] [Related]
9. p14(ARF) inhibits the functions of adenovirus E1A oncoprotein.
Shen J; Zhang S; Li Y; Zhang W; Chen J; Zhang M; Wang T; Jiang L; Zou X; Wong J; Li X; Cui Y; Wang C
Biochem J; 2011 Mar; 434(2):275-85. PubMed ID: 21133853
[TBL] [Abstract][Full Text] [Related]
10. Nucleophosmin protein expression level, but not threonine 198 phosphorylation, is essential in growth and proliferation.
Brady SN; Maggi LB; Winkeler CL; Toso EA; Gwinn AS; Pelletier CL; Weber JD
Oncogene; 2009 Sep; 28(36):3209-20. PubMed ID: 19561638
[TBL] [Abstract][Full Text] [Related]
11. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.
Brady SN; Yu Y; Maggi LB; Weber JD
Mol Cell Biol; 2004 Nov; 24(21):9327-38. PubMed ID: 15485902
[TBL] [Abstract][Full Text] [Related]
12. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
14. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
[TBL] [Abstract][Full Text] [Related]
15. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis.
Chen Z; Carracedo A; Lin HK; Koutcher JA; Behrendt N; Egia A; Alimonti A; Carver BS; Gerald W; Teruya-Feldstein J; Loda M; Pandolfi PP
Sci Signal; 2009 Aug; 2(84):ra44. PubMed ID: 19690330
[TBL] [Abstract][Full Text] [Related]
16. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
[TBL] [Abstract][Full Text] [Related]
17. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
Van Maerken T; Vandesompele J; Rihani A; De Paepe A; Speleman F
Cell Death Differ; 2009 Dec; 16(12):1563-72. PubMed ID: 19779493
[TBL] [Abstract][Full Text] [Related]
18. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.
Carr J; Bell E; Pearson AD; Kees UR; Beris H; Lunec J; Tweddle DA
Cancer Res; 2006 Feb; 66(4):2138-45. PubMed ID: 16489014
[TBL] [Abstract][Full Text] [Related]
19. A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.
Wang J; He X; Luo Y; Yarbrough WG
Biochem J; 2006 Jan; 393(Pt 2):489-501. PubMed ID: 16173922
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.
Agrawal A; Yang J; Murphy RF; Agrawal DK
Exp Mol Pathol; 2006 Oct; 81(2):115-22. PubMed ID: 16919268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]